Pivotal results from uniQure’s gene therapy for Huntington’s disease have brought new light to patients who have known only ...

One of the most devastating diseases finally has a treatment that can slow its progression and transform lives, tearful ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the ...

LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...

Researchers announce breakthrough results for AMT-130, the first disease-modifying treatment for Huntington's disease, with ...

An experimental gene therapy slowed Huntington’s by up to 75 percent in a small clinical trial. While not a cure, it may give patients longer lives.

Scientists have slowed the progression of Huntington’s disease for the first time with a “groundbreaking” new treatment. Experts from University College London (UCL) said the finding could “change ...

UniQure stock crashed Monday on "confusing" and "unexpected" feedback from the FDA for its Huntington's disease gene therapy.

However, in late September 2025, scientists successfully treated Huntington’s for the first time in a ground-breaking study.

Jagadeesha's brain, the first juvenile Huntington's Disease donation in India, offers hope for vital neurodegenerative research at NIMHANS.

An experimental new gene therapy for Huntington’s disease has shown promising results in phase I/II trials, with 75 percent less disease progression observed in the patients receiving the treatment.

Researchers and families unite to address Huntington's disease, exploring innovative therapies and fostering connections at ...